skip to Main Content


Fulfilling the promise of biosimilars has proven more elusive than initially expected. Learn how healthcare stakeholders are evaluating a biosimilars market.

Note on Avalere’s Recent Biosimilars Policy Modeling

Avalere was recently commissioned to project how policy proposals related to biosimilars would impact government spending and patient costs, including modeling and scoring analyses created for 3 proposals publicly released by the Biosimilars Forum in May 2019.

Commercial Uncertainty Remains as U.S. Biosimilar Pipeline Matures

With the recent announcement of the U.S. Food and Drug Administration's (FDA) acceptance of a submission for approval of a second biosimilar to Remicade (infliximab), questions remain for biologics manufacturers, payers, prescribers, and others as to how a mature biosimilars pipeline will begin to evolve in the United States and whether a sustainable competitive specialty market will develop.

Back To Top